What does C4 Therapeutics do?

C4 Therapeutics (C4T) is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.

Is C4 Therapeutics a public company?

(C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public offering of 11.04 million shares of common stock, including the full exercise of the underwriters’ …

What is targeted protein degradation?

Targeted protein degradation is an emerging therapeutic modality whereby small-molecule ligands are used to redirect the cellular protein homeostasis machinery. As part of cellular processes, proteins are specifically recruited to E3 ubiquitin ligases and tagged for destruction with chains of ubiquitin1,2.

How does targeted protein degradation work?

How does Targeted Protein Degradation work? The control of protein levels is accomplished with a small molecule drug called a degrader. Because the degrader molecule is not destroyed by the proteasome, each degrader can cause the destruction of many copies of the harmful protein.

Who founded C4?

Jay Bradner
C4 was founded on the work of Jay Bradner, currently president of the Novartis Institutes for BioMedical Research (NIBR), while he was a researcher at the Dana Farber Cancer Institute, and Nathanael Gray, professor of biological chemistry and molecular pharmacology at Harvard Medical School and an investigator at Dana …

When did C4 go public?

C4 Therapeutics stock is traded on the NASDAQ Global Market under the ticker symbol CCCC. The Company’s Initial Public Offering (IPO) was priced on October 1, 2020.

Who makes C4 energy drink?

Cellucor
BRYAN, Texas — Cellucor, the makers of America’s #1 selling Pre-workout, C4, announced today the launch of its first On The Go Carbonated pre-workout drink. Combining great taste with zero sugar, calories and carbs, C4 On The Go Carbonated will hit shelves nationwide April 30.

What is the importance of protein degradation?

The levels of proteins within cells are determined not only by rates of synthesis, but also by rates of degradation. The half-lives of proteins within cells vary widely, from minutes to several days, and differential rates of protein degradation are an important aspect of cell regulation.

How do you know if your protein is degraded?

If your protein is degraded, you expect to see multiple immunoreactive bands on your blot, just as you did. This can be quite extensive and you may see that many bands that it might look like a smear, but if your resolution is high enough, you should be able to discern the different bands.

How can PROTACs be used for drug discovery?

PROTACs regulate protein function by degrading target proteins instead of inhibiting them, providing more sensitivity to drug-resistant targets and a greater chance to affect the nonenzymatic functions. PROTACs have been proven to show better selectivity compared to classic inhibitors.

Who discovered PROTACs?

Initially described by Kathleen Sakamoto, Craig Crews and Ray Deshaies in 2001, the PROTAC technology has been applied by a number of drug discovery labs using various E3 ligases, including pVHL, Mdm2, beta-TrCP1, cereblon, and c-IAP1. Yale University licensed the PROTAC technology to Arvinas in 2013–14.

https://www.youtube.com/watch?v=hZPLBBYsAKQ